Analysis of PTEN deletions and mutations in multiple myeloma.

Clonal plasma cells from patients with multiple myeloma (MM), plasma cell leukemia (PCL) and human myeloma cell lines (HMCLs) were analyzed for deletions/mutations of the tumor suppressor gene PTEN. By interphase-FISH, hemizygous PTEN deletions were detected in 4 (5.6%) of 71 MM patients, 2 (20%) of 10 PCLs, and 2 (20%) of 10 HMCLs. PTEN deletions were detected in 4 MM patients at diagnosis with stage III disease (Durie-Salmon). Of the six cases with PTEN deletions, 1 MM had a 13q deletion, 1 PCL had a t(11;14), and the other PCL had a t(14;16), a 13q deletion and a p53 deletion. Sequencing analysis did not detect PTEN mutations in 11 primary MM and 5 PCL cases. Our results indicate that alterations of PTEN are uncommon in MM patients, and PTEN deletions tend to occur in advanced disease suggesting that they are secondary, rather than primary, events in the pathogenesis of MM.

[1]  E. Schröck,et al.  Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3 , 1997, Nature Genetics.

[2]  G. Ahmann,et al.  A novel three-color, clone-specific fluorescence in situ hybridization procedure for monoclonal gammopathies. , 1998, Cancer genetics and cytogenetics.

[3]  M. Wigler,et al.  P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[4]  R. Bataille,et al.  High incidence of cryptic translocations involving the Ig heavy chain gene in multiple myeloma, as shown by fluorescence in situ hybridization , 1999, Genes, chromosomes & cancer.

[5]  A. Stewart,et al.  Frequent monoallelic loss of D13S319 in multiple myeloma patients shown by interphase fluorescence in situ hybridization , 1999, Leukemia.

[6]  M. Fiegl,et al.  Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. , 1998, Blood.

[7]  E. Schröck,et al.  Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. , 1998, Blood.

[8]  H. Kaufmann,et al.  Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. , 2000, Blood.

[9]  P. Guldberg,et al.  Mutational analysis of the tumour suppressor gene MMAC1/PTEN in malignant myeloid disorders , 2000, European journal of haematology.

[10]  S. Rudikoff,et al.  Expression of PTEN in PTEN-deficient multiple myeloma cells abolishes tumor growth in vivo , 2000, Oncogene.

[11]  E. Jaffe,et al.  PTEN Gene Alterations in Lymphoid Neoplasms , 1998 .

[12]  Jan-Gowth Chang,et al.  Mutation analysis of PTEN/MMAC1 in acute myeloid leukemia , 2000, American journal of hematology.

[13]  A. Lichtenstein,et al.  Preferential killing of PTEN-null myelomas by PI3K inhibitors through Akt pathway , 2003, Oncogene.

[14]  H. Kittler,et al.  Predictive role of interphase cytogenetics for survival of patients with multiple myeloma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  L. Blanco,et al.  Fidelity of phi 29 DNA polymerase. Comparison between protein-primed initiation and DNA polymerization. , 1993, The Journal of biological chemistry.

[16]  M. Wigler,et al.  PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer , 1997, Science.

[17]  José Luis de la Pompa,et al.  Negative Regulation of PKB/Akt-Dependent Cell Survival by the Tumor Suppressor PTEN , 1998, Cell.

[18]  B. Monia,et al.  PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells , 2002, Oncogene.

[19]  W. K. Alfred Yung,et al.  Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers , 1997, Nature Genetics.

[20]  M. Rue,et al.  Clinical and biologic implications of recurrent genomic aberrations in myeloma. , 2003, Blood.

[21]  P. L. Bergsagel,et al.  Chromosome translocations in multiple myeloma , 2001, Oncogene.

[22]  D. Reece,et al.  p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. , 2004, Blood.

[23]  D. Reece,et al.  The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant , 2004, British journal of haematology.

[24]  M. Butler,et al.  Analysis of PTEN mutations and deletions in B‐cell non‐Hodgkin's lymphomas , 1999, Genes, chromosomes & cancer.